To Evaluate the Efficacy and Safety of ADVAGRAF® After Treatment With a Tacrolimus in New Liver Transplant Recipients
Status:
Completed
Trial end date:
2017-12-14
Target enrollment:
Participant gender:
Summary
This study's objective is to evaluate the incidence rate of acute rejection reactions after
24 weeks treatment with ADVAGRAF® following 3 months treatment with tacrolimus in new liver
transplant recipients.
Treatment conversion will take place from twice daily tacrolimus to once daily tacrolimus
(ADVAGRAF) 3 months after transplant in new liver transplant recipients.